{"id":698710,"date":"2024-05-13T18:10:01","date_gmt":"2024-05-13T18:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=698710"},"modified":"2024-05-13T18:10:01","modified_gmt":"2024-05-13T18:10:01","slug":"wet-agerelated-macular-degeneration-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/wet-agerelated-macular-degeneration-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated_698710.html","title":{"rendered":"Wet Age-Related Macular Degeneration Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1715604018.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Wet Age-Related Macular Degeneration Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1715604018.jpeg\" alt=\"Wet Age-Related Macular Degeneration Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;&ldquo;<strong>Wet Age-Related Macular Degeneration Pipeline Insight 2024<\/strong>&rdquo;&nbsp;report provides comprehensive insights about&nbsp;75+ companies and 80+ pipeline drugs&nbsp;in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.<\/li>\n<li>The leading Wet Age-Related Macular Degeneration companies working in the market include Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.<\/li>\n<li>Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis&reg;, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.<\/li>\n<li>May 2024:- Kodiak Sciences Inc.- A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD). This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD).<\/li>\n<li>May 2024:- Neuracle Genetics Inc.- A Phase 1\/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration. This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).<\/li>\n<li>May 2024:- Outlook Therapeutics Inc.- Safety and Effectiveness of ONS-5010 Compared to Lucentis&reg; in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Wet Age-Related Macular Degeneration @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Wet Age-Related Macular Degeneration &nbsp;Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Wet Age-Related Macular Degeneration Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10&ndash;20% of individuals, it progresses to the wet type. The dry (atrophic) type affects approximately 80&ndash;90% of individuals with AMD. Its cause is unknown, it tends to progress more slowly than the wet type, and there is no approved treatment or cure.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The goals of wet AMD treatment are to slow progression, preserve existing vision, and reverse vision loss if possible. Management of Wet AMD is done through anti-VEGF medications, photocoagulation, and \/or photodynamic therapy. The choice of other treatments depends on the size, location, and type of neovascularization. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye. Low vision rehabilitation can also be an effective part of a wet AMD treatment plan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Wet Age-Related Macular Degeneration Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Abicipar pegol: Molecular Partners<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Abicipar pegol is a long-acting anti-VEGF therapeutic candidate, which was invented by Molecular Partners and initially licensed to Allergan in 2011. The program has been through two positive Phase III studies, CEDAR and SEQUOIA, which supported the non-inferior efficacy of the Abicipar quarterly dosing regimen to maintain vision gains with more than 50 percent fewer injections versus ranibizumab (13 vs. 6) dosed monthly in the first year.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>SOK583A1: Sandoz<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">BA9101 (LY09004), a biosimilar for Eylea, is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, indicated for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR) in patients with diabetic macular edema, and visual impairment due to pathological myopia secondary to choroidal neovascularization(PM-CNV).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ADVM-022: Adverum Biotechnologies<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ADVM-022 is a recombinant, replication-deficient adeno virus-associated (AAV) gene therapy. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 (AAV.7m8-aflibercept) is administered as a single, in-office intravitreal (IVT) injection, designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for patients with wet AMD and DME. The therapeutic candidate is in Phase II clinical studies for wet AMD.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about Wet Age-Related Macular Degeneration in clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Wet Age-Related Macular Degeneration Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Wet Age-Related Macular Degeneration Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 75+ key companies which are developing the therapies for Wet Age-related Macular Degeneration. The companies which have their Wet Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Preregistration include, Molecular Partners.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Wet Age-Related Macular Degeneration pipeline report covers around&nbsp;80+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about Wet Age-Related Macular Degeneration in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Wet Age-Related Macular Degeneration Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Wet Age-Related Macular Degeneration Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Wet Age-Related Macular Degeneration, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Wet Age-Related Macular Degeneration Segmentation<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Wet Age-Related Macular Degeneration Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Wet Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Wet Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Wet Age-Related Macular Degeneration Companies- Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.<\/li>\n<li>Wet Age-Related Macular Degeneration Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis&reg;, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Wet Age-Related Macular Degeneration Pipeline Therapeutics, reach out @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Wet Age-Related Macular Degeneration Products Development<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Wet Age-related Macular Degeneration: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Wet Age-related Macular Degeneration&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Preregistration)<\/li>\n<li>Abicipar pegol: Molecular Partners<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>SOK583A1: Sandoz<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>ADVM-022: Adverum Biotechnologies<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Wet Age-related Macular Degeneration- Unmet Needs<\/li>\n<li>Wet Age-related Macular Degeneration- Market Drivers and Barriers<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=wet-agerelated-macular-degeneration-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=wet-agerelated-macular-degeneration-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;Wet Age-Related Macular Degeneration Pipeline Insight 2024&rdquo;&nbsp;report provides comprehensive insights about&nbsp;75+ companies and 80+ pipeline drugs&nbsp;in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/wet-agerelated-macular-degeneration-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated_698710.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406],"tags":[],"class_list":["post-698710","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/698710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=698710"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/698710\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=698710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=698710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=698710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}